Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by fuzzyjron Jan 18, 2023 10:42am
231 Views
Post# 35230529

Consequences of a "no" vote: from IR

Consequences of a "no" vote: from IRConsequences of a "no" vote: "If the transaction is not approved, Bioasis would be forced to try to continue to operate as a standalone company. It could also be required to reimburse Midatech for Midatech’s expenses associated with the transaction (up to a maximum amount of $225K). The bridge loans from Lind and Midatech would be payable on June 30, 2023, and Bioasis is also required to resume regular repayments under the original Lind agreement starting in January 2023. Both the bridge loans and the Lind agreement are now secured by a pledge of all of Bioasis’ assets. In order to repay the bridge loans and to make the regular monthly payments under the Lind agreement, as well as to fund ongoing operations, Bioasis would need to immediately attempt to secure additional financing. Given current market conditions, it is unlikely that Bioasis would be successful in securing such funding and, even if any funding is available, it would likely be on terms that will be highly dilutive to existing shareholders. If Bioasis cannot raise additional funding, it would likely default on its obligations under the bridge loans and the Lind agreement and Lind and Midatech would be entitled to enforce their rights as secured creditors, which could include enforcing on their security interests and seizing ownership of Bioasis."
<< Previous
Bullboard Posts
Next >>